The patients
Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed, t-AML or AML-MRC1
Vyxeos Liposomal is indicated for the treatment of adults with newly
diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML
with myelodysplasia-related changes (AML-MRC)1
t-AML and AML-MRC are high-risk subtypes of AML2-5
t-AML
previously untreated AML with a history of prior cytotoxic treatment or radiation therapy4,6
AML-MRC
≥20% blood or marrow blasts4 and any of the following:4,7
AML arising from previous MDS or MPN
De novo AML with MDS-related cytogenetic abnormality
De novo AML with multilineage dysplasia†
Up to 1 in 3‡ newly diagnosed patients may fall into these high-risk categories3,8 and could be eligible for treatment with Vyxeos Liposomal1,9
Vyxeos Liposomal is the first chemotherapy in over 40 years to improve survival vs conventional chemotherapy** in patients with high-risk* AML5
- † In the absence of mutations of NPM1 or biallelic mutation of CEBPA4
- ‡ t-AML: ~7% of AML cases3, AML-MRC: ~25% of AML cases8
- * High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
- ** Comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given
- MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm
This website is intended for European Healthcare Professionals only.
REFERENCES
- Vyxeos Liposomal. European Summary of Product Characteristics.
- Boddu PC et al. Cancer 2017;123(16):3050-60.
- Granfeldt Østgård LS et al. J Clin Oncol 2015;33(31):3641-9.
- Arber DA et al. Blood 2016;127(20):2391-405.
- Lancet JE et al. J Clin Oncol 2018;36(26):2684-92.
- National Cancer Institute. Cancer Terms. Available from: www.cancer.gov/publications/dictionaries/cancer-terms/def/t-aml. Accessed May 2020.
- Weinburg OK et al. Blood 2009;113(9):1906-8.
- Nagel G et al. Ann Hematol 2017;96(12):1993-2003.
- Drummond MW. Int J Hematol 2019;8(2):IJH16.
